{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:08:27Z","timestamp":1790806107499,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T00:00:00Z","timestamp":1778976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.breast.2026.104818","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:15:32Z","timestamp":1779290132000},"page":"104818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Real-world use of neratinib as extended adjuvant therapy in HER2-positive early-stage breast cancer: a multicentre study in mainland China and Hong Kong"],"prefix":"10.1016","volume":"88","author":[{"given":"Nilupai","family":"Abudureheiyimu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueran","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zexi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxia","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting Ying","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoqiong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanying","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.breast.2026.104818_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.breast.2026.104818_bib2","first-page":"287","article-title":"Global burden of female breast cancer: new estimates in 2022, temporal trend and future projections up to 2050 based on the latest release from GLOBOCAN","volume":"5","author":"Zhang","year":"2025","journal-title":"J Natl Cancer Cent"},{"issue":"MAY","key":"10.1016\/j.breast.2026.104818_bib3","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fonc.2018.00156","article-title":"Efficacy of anti-HER2 agents in combination with adjuvant or neoadjuvant chemotherapy for early and locally advanced HER2-positive breast cancer patients: a network meta-analysis","volume":"8","author":"Debiasi","year":"2018","journal-title":"Front Oncol"},{"issue":"34","key":"10.1016\/j.breast.2026.104818_bib4","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.1200\/JCO.2009.22.0962","article-title":"Clinical relevance of HER2 overexpression\/amplification in patients with small tumor size and node-negative breast cancer","volume":"27","author":"Curigliano","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104818_bib5","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/cam4.167","article-title":"HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort","volume":"3","author":"Rouanet","year":"2014","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.breast.2026.104818_bib6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/GCO.0b013e328012980a","article-title":"HER2\/neu role in breast cancer: from a prognostic foe to a predictive friend","volume":"19","author":"Ferretti","year":"2007","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.breast.2026.104818_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/11782234241234418","article-title":"Standard-of-Care treatment for HER2+ metastatic breast cancer and emerging therapeutic options","volume":"18","author":"Premji","year":"2024","journal-title":"Breast Cancer Basic Clin Res"},{"issue":"2","key":"10.1016\/j.breast.2026.104818_bib8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0149-2918(00)88288-0","article-title":"Trastuzumab, a recombinant DNA-Derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer","volume":"21","author":"Goldenberg","year":"1999","journal-title":"Clin Ther"},{"issue":"33","key":"10.1016\/j.breast.2026.104818_bib9","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","article-title":"Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2\u2013Positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831","volume":"32","author":"Perez","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.breast.2026.104818_bib10","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.breast.2026.104818_bib11","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","article-title":"Tailoring Therapies\u2014Improving the management of early breast cancer: St gallen international expert consensus on the primary therapy of early breast cancer 2015","volume":"26","author":"Coates","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104818_bib12","doi-asserted-by":"crossref","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","article-title":"Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Senkus","year":"2015","journal-title":"Ann Oncol"},{"issue":"10075","key":"10.1016\/j.breast.2026.104818_bib13","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"25","key":"10.1016\/j.breast.2026.104818_bib14","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1200\/JCO.2011.35.0868","article-title":"Four-year Follow-Up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2\u2013Positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31","volume":"29","author":"Perez","year":"2011","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.breast.2026.104818_bib15","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1038\/sj.onc.1210379","article-title":"Trastuzumab: triumphs and tribulations","volume":"26","author":"Nahta","year":"2007","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.breast.2026.104818_bib16","doi-asserted-by":"crossref","first-page":"737","DOI":"10.3390\/cancers11060737","article-title":"Preclinical characteristics of the irreversible Pan-HER kinase inhibitor neratinib compared with lapatinib: implications for the treatment of HER2-Positive and HER2-Mutated breast cancer","volume":"11","author":"Collins","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.breast.2026.104818_bib17","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.clbc.2016.05.016","article-title":"Neratinib, A novel HER2-Targeted tyrosine kinase inhibitor","volume":"16","author":"Tiwari","year":"2016","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"10.1016\/j.breast.2026.104818_bib18","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.breast.2026.104818_bib19","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-04-2476","article-title":"Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma","volume":"11","author":"Mimura","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.breast.2026.104818_bib20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clbc.2020.09.014","article-title":"Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial","volume":"21","author":"Chan","year":"2021","journal-title":"Clin Breast Cancer"},{"issue":"12","key":"10.1016\/j.breast.2026.104818_bib21","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S1470-2045(17)30717-9","article-title":"Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-Year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"18","author":"Martin","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104818_bib22","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.breast.2022.12.003","article-title":"Final findings from the CONTROL trial: strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer","volume":"67","author":"Chan","year":"2023","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104818_bib23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejca.2023.02.002","article-title":"Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"184","author":"Holmes","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2026.104818_bib24","unstructured":"FDA approves neratinib for extended adjuvant treatment of early stage HER2-positive breast cancer."},{"issue":"7","key":"10.1016\/j.breast.2026.104818_bib25","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/jamaoncol.2021.1371","article-title":"Three-year Follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2 -Positive breast cancer: a secondary analysis of the TRAIN-2 randomized, phase 3 trial","volume":"7","author":"Van Der Voort","year":"2021","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.breast.2026.104818_bib26","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","article-title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","volume":"17","author":"Gianni","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104818_bib27","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.20.01204","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-Positive breast cancer in the APHINITY trial: 6 years\u2019 Follow-Up","volume":"39","author":"Piccart","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.breast.2026.104818_bib28","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-Positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104818_bib29","doi-asserted-by":"crossref","first-page":"18","DOI":"10.21037\/tbcr-24-31","article-title":"Chinese society of clinical oncology (CSCO) breast cancer guidelines 2024","volume":"5","author":"Li","year":"2024","journal-title":"Transl breast cancer Res a J Focus Transl Res breast cancer"},{"issue":"Supplement_7","key":"10.1016\/j.breast.2026.104818_bib30","doi-asserted-by":"crossref","first-page":"vii54","DOI":"10.1093\/rheumatology\/key109","article-title":"Randomized controlled trials and real-world data: differences and similarities to untangle literature data","volume":"57","author":"Monti","year":"2018","journal-title":"Rheumatology"},{"issue":"8","key":"10.1016\/j.breast.2026.104818_bib31","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2217\/fon-2020-0951","article-title":"Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer","volume":"17","author":"Nazha","year":"2021","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104818_bib32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10549-018-05102-x","article-title":"The characterization, management, and future considerations for ErbB-family TKI-Associated diarrhea","volume":"175","author":"Rugo","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"10.1016\/j.breast.2026.104818_bib33","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.annonc.2020.05.012","article-title":"Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial","volume":"31","author":"Barcenas","year":"2020","journal-title":"Ann Oncol"},{"issue":"4_Supplement","key":"10.1016\/j.breast.2026.104818_bib34","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS25-PS3-11-21","article-title":"A real-world prospective observational multi-national study in adult patients with breast cancer treated with extended adjuvant neratinib: interim results from the NERLYFE study","volume":"32","author":"Baerens","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.breast.2026.104818_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000533657","article-title":"Neratinib as extended adjuvant treatment of HER2-Positive\/HR-Positive early breast cancer patients in Germany, Austria, and Switzerland: interim results of the prospective, observational ELEANOR study","volume":"19","author":"Harbeck","year":"2024","journal-title":"Breast Care"},{"key":"10.1016\/j.breast.2026.104818_bib36","article-title":"309P A multicenter, prospective, non-interventional study to investigate the treatment patterns of neratinib in human epidermal growth factor receptor 2 positive (HER2+) early breast cancer (EBC) in China: interim analysis of the NER-tree study","volume":"35","author":"Wang","year":"2024","journal-title":"Ann Oncol"},{"issue":"12_Supplement","key":"10.1016\/j.breast.2026.104818_bib37","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-P3-11-22","article-title":"Abstract P3-11-22: extended adjuvant neratinib in HER2+\/HR+ early breast cancer (eBC) in clinical routine \u2013 interim analysis of the multinational, prospective, non-interventional study ELEANOR (n=300)","volume":"31","author":"L\u00fcftner","year":"2025","journal-title":"Clin Cancer Res"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T21:29:54Z","timestamp":1784928594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626001281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":37,"alternative-id":["S0960977626001281"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104818","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world use of neratinib as extended adjuvant therapy in HER2-positive early-stage breast cancer: a multicentre study in mainland China and Hong Kong","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104818","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104818"}}